An Open-Label, Phase I, Randomized Pharmacokinetic Study of Dietary Effects on Abiraterone Acetate Drug Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (DEAL)
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Acronyms DEAL
- 05 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 05 Jan 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 07 Aug 2013 New trial record